| Project/Area Number |
15K08912
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine(including psychosomatic medicine)
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Hagihara Keisuke 大阪大学, 医学系研究科, 特任教授(常勤) (60423183)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岸田 友紀 大阪大学, 医学系研究科, その他 (20423163)
中西 美保 滋賀医科大学, 医学部, 助教 (40382048)
|
|---|
| Research Collaborator |
NUNOMURA Kazuto 大阪大学, 薬学研究科, 特任研究員
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | iPS細胞 / ドラッグリポジショニング / サルコペニア |
|---|
| Outline of Final Research Achievements |
Frailty, means the elders who need care in the near future, Sarcopenia has been noted in the physical aspect of frailty. We already reported the effect of Go-sha-jinki-Gan (GJG) on sarcopenia by using senescence-accelerated mice (SAMP8) via normalizing signal transduction through the IGF-1-Akt axis, mitochondrial-related transcription factors, and suppressed TNF-α. We investigated an active ingredient derived from components of GJG as a candidate of anti-sarcopenic drug. We established iPS cell lines derived from SAMP8 mice, however, the effect of GJG on C2C12 cells, a mice muscle cell line, was weak using several in vitro assays. Next, we focused on the anti-inflammatory effect of GJG. GJG showed an inhibitory effect on the production of TNF-α in SAMP 8 mouse and mouse macrophage-like cell line RAW 264.7 cells. Cinnamaldehyde derived from Cinnamon Bark and Chikusetsususaponin - V derived from Achyranthes Root could be a candidate for new anti - sarcopenia agent.
|
